Skip to content
Review Open access

From seeds to symptoms: the molecular landscape of tau seeding in Alzheimer’s disease

Sep 2026 · Frontiers in Neuroscience · Vol 20 · 0 citations · 225 references
Medicine

TL;DR

Recent progress in tau seeding research is summarized, highlighting both intrinsic and extrinsic regulators of tau prion-like activity and therapeutic strategies targeting tau pathology.

Abstract

Alzheimer’s disease (AD) is the leading cause of dementia in the elderly, pathologically defined by extracellular amyloid-β plaques and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. The Braak staging system established that tau pathology spreads in a stereotypical pattern across the brain, supporting the “prion-like” hypothesis: misfolded tau aggregates serve as seeds, inducing the misfolding and aggregation of normal tau, and thereby driving disease progression along neuroanatomical pathways. In the past 5 years (2021–2026), substantial advances have elucidated the molecular mechanisms underlying tau seeding activity. This review summarizes recent progress in tau seeding research, highlighting both intrinsic and extrinsic regulators of tau prion-like activity. Intrinsic factors include the structural basis of tau strains, MAPT mutations, alternative splicing (3R/4R isoforms), post-translational modifications, and liquid–liquid phase separation. Extrinsic factors encompass cofactors, molecular chaperones, non-coding RNAs, epigenetic mechanisms, environmental exposures, and the emerging concept of trans-seeding by heterologous protein fibrils. We also review therapeutic strategies targeting tau pathology, focusing on their mechanisms and clinical development. Integrating these mechanistic insights and therapeutic advances will inform future research and clinical strategies for AD and related tauopathies.

Read PDF

Similar papers

Review Aug 2026

Tau dysfunction in alzheimer’s disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives

Findings support a model in which tau dysfunction results from the convergence of molecular aberrations and genetic susceptibility within a pathological network involving amyloid-β, neuroinflammation, and synaptic failure.

S. Sura, S. Jagadeesan, M. A. M. Moklas et al. · 0 citations
Review Open access Sep 2026

Tau phosphorylation in Alzheimer’s disease: emerging mechanisms, network interactions, and therapeutic implications

While amyloid-β (Aβ) has historically dominated the research landscape of Alzheimer’s disease (AD), the limited clinical success of Aβ-centric therapies has redirected focus toward tau pathology, which correlates more robustly with cognitive deterioration and synaptic dysfunction. Transcending the traditional linear...

Xue Li, Lei-Han Zhang, Li-Jun Zhao et al. · 0 citations
Review Open access Aug 2026

Tau Protein Pathology and Tau-Targeted Therapeutic Strategies in Alzheimer’s Disease: Mechanisms, Clinical Evidence and Future Perspectives

Though no tau-targeted therapy has yet to demonstrate definitive clinical benefit, continued research supports tau as an important therapeutic target and contributes to the development of more effective treatments for AD.

Zhuo-Yu Wang · 0 citations
Open access Sep 2026

A scalable human neuron model of Alzheimer’s disease relevant tauopathy reveals mechanisms linking Tau fibrillization to synaptic dysfunction

The development of scalable iPSC-neuron models enables tauopathy drug discovery and reconstructs progressive Tau seeding, fibrillization and synaptic dysfunction, and establishes a physiologically relevant, scalable platform for therapeutic screening that connects Tau seed uptake, site-specific phosphorylation, fibril...

J. Lipka, Xiwei Shan, Qiao Zhang et al. · 0 citations
Open access Sep 2026

Conformation-specific anti-pathological tau antibody raised against AD brain-derived seed-competent tau reduces tau pathology in transgenic mice

It is revealed that only a low abundant and rare subset of tau species is involved in seeding activity and that this species can be used to raise a conformation- and pathology-specific-antibody against tau.

K. Yanamandra, N. Romanul, Hiral Patel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.